Effective Treatment of a Metastatic Thymic Neuroendocrine Tumor with Capecitabine and Temozolomide: A Case Report

#449

Introduction: Thymic neuroendocrine tumors are rare, with an estimated annual incidence of 0.2 per million. They are generally considered chemoresistant and there have been no reported cases of an objective response to therapy.

Aim(s): To review a case of a metastatic neuroendocrine tumor of the thymus in which an objective partial radiographic response was obtained using systemic chemotherapy consisting of capecitabine and temozolomide.

Materials and methods: Case report with clinicopathologic reivew and radiographic evaluation of response using RECIST 1.1 criteria.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: SarangaPerry V, Morse B, Kvols L, Strosberg J,

Keywords: neuroendocrine tumor, thymus, capecitabine, temozolomide,

To read the full abstract, please log into your ENETS Member account.